Satellos Eyes Nasdaq with $50M Offering to Fund DMD Drug

TORONTO, ON – February 05, 2026 – Satellos Bioscience, a Toronto-based clinical-stage biotechnology company, is making a pivotal move to accelerate its fight against degenerative muscle diseases, announcing a proposed public offering aimed at raising approximately US$50 million alongside an application to list on the U.S. Nasdaq Global Market. The dual strategy is designed to fuel the development of its lead drug candidate, SAT-3247, a novel treatment for Duchenne Muscular Dystrophy (DMD).

The company has priced its offering at US$10.10 per common share. This significant financial maneuver, coupled with the pursuit of a prestigious Nasdaq listing under the ticker 'MSLE', signals a new chapter for Satellos as it seeks to tap into the world's largest capital market to fund its ambitious clinical programs.

A Strategic Leap South for Capital

The move to list on Nasdaq represents a well-trodden path for ambitious Canadian biotechs seeking greater visibility, liquidity, and access to a deeper pool of institutional and retail investors in the United States. To facilitate the listing and meet Nasdaq's minimum share price requirements, Satellos recently executed a 1-for-12 share consolidation, which took effect on the Toronto Stock Exchange (TSX) around January 30, 2026. The company will maintain its TSX listing under the symbol 'MSCL', where its stock has seen impressive returns of 124% over the past six months.

The public offering consists of 4,455,445 common shares and pre-funded warrants for an additional 495,049 shares, targeting gross proceeds of US$50 million before expenses. A syndicate of prominent investment banks, including Leerink Partners, Guggenheim Securities, and Oppenheimer & Co. as joint-book running managers, and Bloom Burton as co-manager, is handling the offering. The underwriters have also been granted a 30-day option to purchase up to an additional 15% of the offered shares, potentially increasing the total capital raised. Trading on Nasdaq is expected to commence on February 6, 2026, pending final approvals.

This cross-border financing highlights a critical trend where Canadian life science firms leverage U.S. exchanges to secure the substantial funding required for the long and expensive journey of drug development, from late-stage clinical trials to commercialization.

Fueling the Future of Muscle Repair

At the heart of this major financial push is SAT-3247, a first-of-its-kind, orally administered small molecule drug. Unlike many treatments for Duchenne Muscular Dystrophy that focus on gene replacement or modification, Satellos' candidate takes a fundamentally different approach. SAT-3247 is designed to restore the body's natural muscle repair and regeneration capabilities.

The drug targets a protein called AAK1, which the company has identified as a key regulator of muscle stem cell activity. In DMD, the absence of the dystrophin protein disrupts the normal signaling that tells stem cells to repair and build muscle tissue. Satellos' research suggests that by inhibiting AAK1 with SAT-3247, it can re-establish those crucial regenerative signals, effectively instructing the body to repair itself. This unique mechanism of action holds the potential to be a disease-modifying therapy for DMD patients, regardless of their specific genetic mutation.

The competitive landscape for DMD treatments is intense, dominated by gene therapies like Sarepta Therapeutics' FDA-approved Elevidys and a class of drugs known as exon-skippers. However, SAT-3247's novel approach to muscle regeneration could position it as a standalone therapy or as a complementary treatment alongside existing options.

The net proceeds from the offering are earmarked to aggressively advance SAT-3247. The funding will support ongoing clinical development, including the BASECAMP Phase 2 pediatric study and the TRAILHEAD long-term DMD study. It will also enable Satellos to progress a planned Phase 2 trial for another muscle-wasting condition, facioscapulohumeral muscular dystrophy (FSHD), and invest in other discovery-stage programs.

An Investor's Perspective: High Risk, High Reward

For investors, Satellos presents the classic clinical-stage biotech profile: a company with a potentially transformative technology facing significant financial and clinical hurdles. The company's recent stock performance on the TSX has been robust, but some market analysis suggests the valuation may be getting ahead of itself, with an InvestingPro report noting the company appears "slightly overvalued" at its current levels.

The company's financial filings paint a picture of a pre-revenue entity with a high cash burn rate. As of September 30, 2025, Satellos had C$34.6 million in cash and short-term investments, down from C$48.5 million at the end of 2024. Its net loss widened to C$28.1 million in 2024 from C$15.9 million in 2023, driven primarily by a surge in R&D expenses as it advanced SAT-3247 into the clinic. This "ongoing funding risk" is precisely what the current US$50 million offering is designed to mitigate, providing a crucial financial runway for the next phases of development.

Adding a layer of confidence for the market, the offering has seen participation from insiders. Two Satellos board members, Franklin Berger and Mark Nawacki, committed to purchasing a combined 54,750 common shares. Furthermore, Bloom Burton Securities, the co-manager of the offering, has a long-standing relationship with the company, having led a previous US$40 million equity offering in December 2024. Entities associated with Bloom Burton collectively hold approximately 7.33% of Satellos' outstanding shares, signaling strong institutional backing.

This infusion of capital is critical for Satellos to navigate the costly path of late-stage clinical trials. The ultimate value of the company will not be determined by its stock market debut on Nasdaq, but by the clinical data that emerges from its trials. The DMD community, along with the broader biotech industry, will be watching closely to see if SAT-3247 can deliver on its promise to regenerate muscle and change the course of this devastating disease. The success of this offering provides the fuel; the upcoming clinical results will determine the journey's destination.